BHU will study the use of Ashwagandha for treatment of Corona patients
Varanasi, 13 July: The Institute of Medical Sciences (IMS) in the Banaras Hindu University (BHU) will examine using Ashwagandha (Withania somnifera) as a test medication for prophylactic usage one of frontline medical workers and Yashtimadhu (Glycyrrhiza glabra) for supplemental treatment as a typical therapy of Corona patients with moderate and mild symptoms.
He explained, “Ashwagandha is going to be analyzed for research in prophylactic usage one of frontline health employees of SSL Hospital of BHU and other health care employees, while Yashtimadhu is going to be analyzed as medication for adjunct treatment with the typical therapy of traditional medication on Covid-19 patients under therapy in BHU with moderate and mild symptoms”
The goals of these projects would be to learn more about the effectiveness of ayurvedic remedies in Covid-19 patients based on criteria of traditional biomedical researchers,” he stated, adding that every centre has shaped joint groups of researchers from allopathy and ayurvedic faculties.
Prof Chaudhary said that the remnant of Ashwagandha and Yashtimadhu was obtained by BHU while capital for additional research and statistics collection to be carried out in six months, are predicted to be allocated inside a week.
He explained that the accumulated data of those studies will be filed for analysis on current scientific criteria by international health agencies such as WHO for its approval of Ayurveda as a method of medicine globally.
BHU, that will be one of 15 institutions of the nation to contribute to the particular project, is supplying level-3 centre in its hospitals to Covid-19 patients whether it’s also conducting lab testing for publication coronavirus disease of several suburban Uttar Pradesh districts.